Literature DB >> 20557939

Bilateral diabetic papillopathy and metabolic control.

Christoffer Ostri1, Henrik Lund-Andersen, Birgit Sander, Ditte Hvidt-Nielsen, Michael Larsen.   

Abstract

OBJECTIVE: The pathogenesis of diabetic papillopathy largely is unknown, but case reports suggest that it may follow rapidly improved metabolic control. The present study was designed to investigate this hypothesis.
DESIGN: Retrospective case-control study. PARTICIPANTS: Two thousand sixty-six patients with type 1 diabetes.
METHODS: Review of clinical, photographic, and clinical chemistry records from a large diabetology and ophthalmology unit between 2001 and 2008. MAIN OUTCOME MEASURES: Simultaneous, bilateral diabetic papillopathy.
RESULTS: The mean follow-up was 4.9 years. During 10,020 patient-years of observation, bilateral diabetic papillopathy developed in 5 patients. During the year preceding this incident, all 5 patients had experienced a decrease in glycosylated hemoglobin A₁(c) (HbA₁(C)) at a maximum rate of -2.5 (mean) percentage points per quarter year, which was significantly different from the changes in HbA₁(C) observed in the remainder of the study population (P<0.001). Photographs recorded before the onset of bilateral diabetic papillopathy showed that all 5 patients had small cup-to-disc diameter ratios in both eyes (P<0.001).
CONCLUSIONS: Diabetic papillopathy was associated markedly with a drastic recent reduction in glycemia and a small cup-to-disc diameter ratio. This supports the hypothesis that diabetic papillopathy may be an early worsening phenomenon occurring in anatomically predisposed patients in response to a recent rapid decrease in glycemia. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.
Copyright © 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20557939     DOI: 10.1016/j.ophtha.2010.03.006

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

1.  Resolution of diabetic papillopathy with a single intravitreal injection of bevacizumab combined with triamcinolone acetonide.

Authors:  Jing Feng; Jin-Feng Qu; Yan-Rong Jiang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-06-26       Impact factor: 3.117

2.  Baseline haemoglobin A1c influences retinal function after long-term insulin pump therapy.

Authors:  Oliver N Klefter; Stig K Holfort; Michael Larsen
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2015-06-25       Impact factor: 3.117

3.  Diabetic papillopathy with macular edema treated with intravitreal bevacizumab.

Authors:  Ahmed S Al-Hinai; Mohammed S Al-Abri; Rayah H Al-Hajri
Journal:  Oman J Ophthalmol       Date:  2011-09

4.  Optic disc swelling and vision loss in a patient with cystic fibrosis and diabetes.

Authors:  Ioulia Iosfina; Jean Y Chuo; Derek V Godinho; Pearce G Wilcox; Stuart H Kreisman; Bradley S Quon
Journal:  Case Rep Endocrinol       Date:  2013-08-19

5.  Diabetic papillopathy with macular edema treated with intravitreal ranibizumab.

Authors:  Moosang Kim; Jang-Hun Lee; Seung-Jun Lee
Journal:  Clin Ophthalmol       Date:  2013-11-27

6.  Impact of changes in metabolic control on progression to photocoagulation for clinically significant macular oedema: a 20 year study of type 1 diabetes.

Authors:  B Sander; M Larsen; E W Andersen; H Lund-Andersen
Journal:  Diabetologia       Date:  2013-08-30       Impact factor: 10.122

7.  Re-evaluating diabetic papillopathy using optical coherence tomography and inner retinal sublayer analysis.

Authors:  Josef Huemer; Hagar Khalid; Daniel Ferraz; Livia Faes; Edward Korot; Neringa Jurkute; Konstantinos Balaskas; Catherine A Egan; Axel Petzold; Pearse A Keane
Journal:  Eye (Lond)       Date:  2021-07-09       Impact factor: 4.456

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.